Ownership and insider activity for Inhibrx Biosciences Inc. (INBX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function.
Price
| Price | $101.77 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | MANHARD KIMBERLY | S-Sale | 500 | $56K |
| 2026-09-14 | MANHARD KIMBERLY | S-Sale | 500 | $55K |
| 2026-09-15 | MANHARD KIMBERLY | S-Sale | 500 | $53K |
| 2026-09-08 | MANHARD KIMBERLY | S-Sale | 500 | $58K |
| 2026-09-09 | MANHARD KIMBERLY | S-Sale | 500 | $58K |
| 2026-09-08 | Kayyem Jon Faiz | P-Purchase | 5,000 | $568K |
| 2026-09-08 | FORSYTH DOUGLAS | P-Purchase | 2,500 | $287K |
| 2026-09-08 | Lappe Mark | P-Purchase | 9,681 | $1.1M |
| 2026-09-08 | Lappe Mark | P-Purchase | 1,219 | $136K |
| 2026-09-08 | Lappe Mark | P-Purchase | 500 | $54K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.0M | $13.5M | $2.1M | $11.5M | $128.7M | $131.3M | $273.9M | $277.9M | $152.6M | $124.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $696000 | $690000 | $438000 | $615000 | $878000 | $257000 | $778000 | $420000 | $177000 |
| Inventory | 0 | $999000 | $2.3M | $3.2M | -$129.3M | -$878000 | 0 | 0 | 0 | 0 |
| Total Current Assets | $20.4M | $15.4M | $5.7M | $15.6M | $132.2M | $139.1M | $280.5M | $295.4M | $160.4M | $132.8M |
| Property, Plant & Equipment | $864000 | $1.8M | $2.6M | $10.7M | $11.3M | $9.5M | $7.2M | $9.4M | $13.5M | $9.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $21.3M | $17.2M | $10.0M | $26.5M | $143.7M | $150.4M | $290.9M | $307.9M | $180.8M | $146.5M |
| Accounts Payable | $167000 | $775000 | $6.5M | $3.1M | $13.5M | $9.1M | $8.3M | $11.0M | $9.2M | $5.9M |
| Short-term Debt | $4.3M | $5.2M | $5.9M | $4.7M | $1.5M | $1.7M | $1.9M | 0 | $1.6M | $2.3M |
| Total Current Liabilities | $5.3M | $8.9M | $16.2M | $20.6M | $31.4M | $22.5M | $27.6M | $56.3M | $40.7M | $33.8M |
| Long-term Debt | $14.7M | $9.5M | $3.6M | $37.1M | $36.0M | $70.5M | $202.1M | $207.0M | 0 | $100.6M |
| Total Liabilities | $20.0M | $39.7M | $67.6M | $120.1M | $68.3M | $98.1M | $232.8M | $264.4M | $47.2M | $138.5M |
| Retained Earnings | -$9.2M | -$28.8M | -$17.9M | -$69.3M | -$145.4M | -$227.1M | -$372.4M | -$613.7M | -$106.1M | -$246.2M |
| Total Equity | -$9.2M | -$28.8M | -$57.6M | -$93.6M | $75.5M | $52.4M | $58.1M | $43.5M | $133.6M | $8.0M |
| Total Debt | $18.9M | $14.7M | $9.5M | $41.7M | $37.5M | $72.1M | $207.1M | $210.1M | $8.0M | $107.0M |
| Net Debt | -$1.1M | $1.2M | $7.4M | $30.2M | -$91.2M | -$59.2M | -$66.8M | -$67.8M | -$144.5M | -$17.2M |
| Working Capital | $15.1M | $6.5M | -$10.5M | -$5.0M | $100.8M | $116.7M | $252.9M | $239.0M | $119.7M | $99.0M |
Financial Health
| Debt / Equity | -0.10 |
| Current Ratio | 5.07 |
Profitability
| Return on Equity | 1893.60% |
| Return on Invested Capital | -99.35% |
| Return on Assets | -89.60% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AMLX · ATAI · CVAC · ELVN · IMTX · NKTR · ORIC
Explore sector: Healthcare · Biotechnology
More sections of INBX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks